Kostas Biliouris
Stock Analyst at Oppenheimer
(2.34)
# 3,108
Out of 4,988 analysts
439
Total ratings
42.8%
Success rate
0.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Reiterated: Buy | $50 → $26 | $9.65 | +169.43% | 4 | Sep 9, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $10 → $20 | $5.18 | +286.10% | 3 | Sep 9, 2026 | |
| TRDA Entrada Therapeutics | Reiterated: Buy | $23 | $6.75 | +240.74% | 5 | Sep 3, 2026 | |
| OVID Ovid Therapeutics | Reiterated: Buy | $9 | $2.69 | +234.57% | 2 | Aug 14, 2026 | |
| PRQR ProQR Therapeutics | Reiterated: Buy | $9 | $1.83 | +391.80% | 4 | Aug 14, 2026 | |
| TSX: MSCL Satellos Bioscience Inc. | Reiterated: Buy | $55.48 | $13.03 | +325.78% | 3 | Aug 14, 2026 | |
| LEGN Legend Biotech | Downgraded: Hold | $75 → $40 | $17.61 | +127.14% | 60 | Aug 12, 2026 | |
| SRPT Sarepta Therapeutics | Reiterated: Buy | $37 → $35 | $20.11 | +74.04% | 38 | Aug 6, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $500 → $350 | $239.56 | +46.10% | 41 | Jul 31, 2026 | |
| PRME Prime Medicine | Reiterated: Buy | $11 | $3.12 | +252.56% | 19 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $25.44 | +10.06% | 2 | Jul 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 | $12.24 | +71.57% | 4 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $6.67 | +199.85% | 21 | Jun 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $2.85 | +426.32% | 3 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 | $10.02 | +119.56% | 18 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $66.61 | - | 12 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $24.95 | - | 23 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $63.94 | - | 31 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $17.11 | - | 5 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $15.22 | - | 30 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $44.44 | - | 27 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.6178 | - | 4 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.10 | - | 9 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $12.14 | - | 25 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.37 | - | 5 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $12.20 | - | 14 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $56.56 | +32.60% | 20 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.07 | n/a | 6 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $77 | $283.49 | n/a | 1 | Jun 16, 2022 |
Evommune
Sep 9, 2026
Reiterated: Buy
Price Target: $50 → $26
Current: $9.65
Upside: +169.43%
Opus Genetics
Sep 9, 2026
Reiterated: Buy
Price Target: $10 → $20
Current: $5.18
Upside: +286.10%
Entrada Therapeutics
Sep 3, 2026
Reiterated: Buy
Price Target: $23
Current: $6.75
Upside: +240.74%
Ovid Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $9
Current: $2.69
Upside: +234.57%
ProQR Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $9
Current: $1.83
Upside: +391.80%
Satellos Bioscience Inc.
Aug 14, 2026
Reiterated: Buy
Price Target: $55.48
Current: $13.03
Upside: +325.78%
Legend Biotech
Aug 12, 2026
Downgraded: Hold
Price Target: $75 → $40
Current: $17.61
Upside: +127.14%
Sarepta Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: $37 → $35
Current: $20.11
Upside: +74.04%
Alnylam Pharmaceuticals
Jul 31, 2026
Reiterated: Buy
Price Target: $500 → $350
Current: $239.56
Upside: +46.10%
Prime Medicine
Jul 24, 2026
Reiterated: Buy
Price Target: $11
Current: $3.12
Upside: +252.56%
Jul 10, 2026
Reiterated: Buy
Price Target: $28
Current: $25.44
Upside: +10.06%
Jun 15, 2026
Reiterated: Buy
Price Target: $21
Current: $12.24
Upside: +71.57%
Jun 9, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $6.67
Upside: +199.85%
Mar 31, 2026
Reiterated: Buy
Price Target: $15
Current: $2.85
Upside: +426.32%
Mar 13, 2026
Reiterated: Buy
Price Target: $22
Current: $10.02
Upside: +119.56%
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $66.61
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $24.95
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $63.94
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $17.11
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $15.22
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $44.44
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $0.6178
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $1.10
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $12.14
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $3.37
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $12.20
Upside: -
Sep 23, 2025
Reiterated: Buy
Price Target: $75
Current: $56.56
Upside: +32.60%
Jan 29, 2024
Rated: Hold
Price Target: n/a
Current: $4.07
Upside: n/a
Jun 16, 2022
Initiated Coverage: Buy
Price Target: $77
Current: $283.49
Upside: n/a